Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dec 23, 2010 (rev. 2)

Premium

Rosetta Genomics said Brian Markison has been named an observer of the company's board.

Pending shareholder approval, he will also become a director, the firm said.

Markison is currently chairman and CEO of King Pharmaceuticals, which was recently acquired by Pfizer. Previously, he held a variety of roles at Bristol-Myers Squibb, including president of oncology/virology and oncology therapeutics.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.